1. TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk
- Author
-
Daniel J. Craig, Erin L. Crawford, Heidi Chen, Eric L. Grogan, Steven A. Deppen, Thomas Morrison, Sanja L. Antic, Pierre P. Massion, and James C. Willey
- Subjects
Lung cancer prevention ,Lung cancer early detection ,Biomarker ,Next generation sequencing ,TP53 ,Lung nodule risk classification ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background There is a need for biomarkers that improve accuracy compared with current demographic risk indices to detect individuals at the highest lung cancer risk. Improved risk determination will enable more effective lung cancer screening and better stratification of lung nodules into high or low-risk category. We previously reported discovery of a biomarker for lung cancer risk characterized by increased prevalence of TP53 somatic mutations in airway epithelial cells (AEC). Here we present results from a validation study in an independent retrospective case–control cohort. Methods Targeted next generation sequencing was used to identify mutations within three TP53 exons spanning 193 base pairs in AEC genomic DNA. Results TP53 mutation prevalence was associated with cancer status (P
- Published
- 2023
- Full Text
- View/download PDF